NCT03833141

Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.

Patient Outcomes Real World Evidence Registry (POWER): Patient Reported Outcomes in a Cohort of Canadian Adults With Severe Eosinophilic Asthma on Benralizumab.

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 170 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 18 Years – 130 Years
• Healthy volunteers: Not accepted

Summary

This study will generate patient reported outcomes (PROs) associated with the use of benralizumab as treatment for severe eosinophilic asthma.

Detailed description

Benralizumab was launched in 2018 following regulatory approval in Canada and is now widely available for Canadian patients with severe eosinophilic asthma. This study is an observational cohort study of patient reported outcomes (PROs) within real-world settings for participants who are prescribed benralizumab for treatment of uncontrolled severe eosinophilic asthma. Patients will be recruited in select clinics across Canada. Survey data for each participant in the study will be obtained at the following time-points: * Baseline (Week 0) * Short-term follow up: 1-, 2-, 4-, and 8-weeks after baseline * Long-term follow-up: 24- and 56-weeks after baseline

Conditions

• Severe Eosinophilic Asthma

Interventions

Type	Name	Description
OTHER	Survey Administration	Patient Reported Outcomes (PROs) of health, quality of life, and economic outcomes during routine clinical practice.

Timeline

• Start date: 2018-11-12
• Primary completion: 2024-05-28
• Completion: 2024-05-28
• First posted: 2019-02-06
• Last updated: 2024-07-01

Locations

20 sites across 1 country: Canada

Regulatory

• FDA-regulated drug study